Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro
- PMID: 1337893
- DOI: 10.1007/BF01961133
Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro
Abstract
The effects of different antiviral drug combinations on the replication of various human cytomegalovirus (CMV) strains in human embryonic lung (HEL) fibroblasts were evaluated. HPMPC combined with either ganciclovir, foscarnet or acyclovir showed additive to synergistic inhibition of CMV replication. Combinations of zidovudine with HPMPC, ganciclovir, foscarnet or acyclovir also resulted in additive to synergistic inhibition of CMV replication. Synergism tended to be higher for the clinical CMV isolates than for the reference strains AD-169 and Davis. Suppression of CMV replication was obtained at lower drug concentrations when the drugs were combined than when the drugs were used alone. At the highest drug concentrations used in the antiviral activity experiments, neither drug alone nor its combination suppressed host cell growth. If higher drug concentrations were used, zidovudine increased the inhibitory effects of ganciclovir, acyclovir and foscarnet but not of HPMPC, on cell proliferation. Use of combinations in the therapy of CMV infections may be considered to enhance drug efficacy, to reduce toxicity and, possibly, to diminish the risk of emergence of drug-resistant virus strains.
Similar articles
-
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007. Drugs. 1994. PMID: 7527325 Review.
-
New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.Verh K Acad Geneeskd Belg. 1994;56(6):561-92. Verh K Acad Geneeskd Belg. 1994. PMID: 7892749
-
In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.Antimicrob Agents Chemother. 2014;58(2):986-94. doi: 10.1128/AAC.01972-13. Epub 2013 Nov 25. Antimicrob Agents Chemother. 2014. PMID: 24277030 Free PMC article.
-
Effects of acyclovir combined with other antiviral agents on human cytomegalovirus.Am J Med. 1982 Jul 20;73(1A):36-9. doi: 10.1016/0002-9343(82)90060-2. Am J Med. 1982. PMID: 6179416
-
Is combination antiviral therapy for CMV superior to monotherapy?J Clin Virol. 2006 Apr;35(4):485-8. doi: 10.1016/j.jcv.2005.09.021. Epub 2006 Jan 18. J Clin Virol. 2006. PMID: 16387546 Review.
Cited by
-
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007. Drugs. 1994. PMID: 7527325 Review.
-
Therapeutic Drug Monitoring of Ganciclovir: Where Are We?Ther Drug Monit. 2022 Feb 1;44(1):138-147. doi: 10.1097/FTD.0000000000000925. Ther Drug Monit. 2022. PMID: 34610621 Free PMC article. Review.
-
Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy.Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01627-20. doi: 10.1128/AAC.01627-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33077661 Free PMC article.
-
Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS.Drugs. 1999 Aug;58(2):325-45. doi: 10.2165/00003495-199958020-00015. Drugs. 1999. PMID: 10473024 Review.
-
Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.Drugs. 1994 Jan;47(1):153-205. doi: 10.2165/00003495-199447010-00009. Drugs. 1994. PMID: 7510619 Review.